ORGANOGENESIS HOLDINGS INC. (ORGO) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | Gross Profit |
| Revenue | 457.45M USD | |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $457.45M | (m) | (m) |
| 2026-03-31 | (m) | $514.70M | (m) | (m) |
| 2025-12-31 | (m) | $564.17M | (m) | (m) |
| 2025-09-30 | (m) | $465.22M | (m) | (m) |
| 2025-06-30 | (m) | $429.53M | (m) | (m) |
| 2025-03-31 | $347.99M | $458.76M | (m) | 75.85% |
| 2024-12-31 | $366.30M | $482.04M | (m) | 75.99% |
| 2024-09-30 | $342.58M | $455.04M | (m) | 75.29% |
| 2024-06-30 | $336.94M | $448.39M | (m) | 75.14% |
| 2024-03-31 | $326.90M | $435.47M | (m) | 75.07% |
| 2023-12-31 | $326.66M | $433.14M | (m) | 75.42% |
| 2023-09-30 | $343.18M | $449.00M | (m) | 76.43% |
| 2023-06-30 | $351.12M | $457.33M | (m) | 76.78% |
| 2023-03-31 | $354.87M | $461.42M | (m) | 76.91% |
| 2022-12-31 | $345.87M | $450.89M | (m) | 76.71% |
| 2022-09-30 | $352.73M | $463.24M | (m) | 76.14% |
| 2022-06-30 | $349.63M | $460.13M | (m) | 75.99% |
| 2022-03-31 | $349.84M | $463.62M | (m) | 75.46% |
| 2021-12-31 | $353.86M | $468.06M | (m) | 75.60% |
| 2021-09-30 | $339.19M | $446.31M | (m) | 76.00% |
| 2021-06-30 | $329.44M | $433.35M | (m) | 76.02% |
| 2021-03-31 | $285.10M | $379.12M | (m) | 75.20% |
| 2020-12-31 | $250.98M | $338.30M | (m) | 74.19% |
| 2020-09-30 | $223.95M | $306.14M | (m) | 73.15% |
| 2020-06-30 | $191.25M | $269.60M | (m) | 70.94% |
| 2020-03-31 | $187.83M | $265.59M | (m) | 70.72% |
| 2019-12-31 | $185.03M | $260.98M | (m) | 70.90% |
| 2019-09-30 | $176.87M | (m) | (m) | (m) |
| 2019-06-30 | $163.03M | (m) | (m) | (m) |
| 2019-03-31 | $143.78M | (m) | (m) | (m) |
| 2018-12-31 | $124.64M | $193.45M | (m) | 64.43% |
| 2018-09-30 | (m) | $0.00 | (m) | (m) |
| 2018-06-30 | (m) | $0.00 | (m) | (m) |
| 2018-03-31 | (m) | $0.00 | (m) | (m) |
| 2017-12-31 | (m) | $0.00 | (m) | (m) |
| 2017-09-30 | (m) | $0.00 | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $0.00 | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |